The novel antitumor antibiotics PD 114,759 and PD115,028 were evaluated for their ability to cause repairable DNAdamage and the induction of SOS functions in bacterial systems. PD 114,759 and PD 115,028 were preferentially toxic to DNArepair-defective Escherichia coli WP100uvrA recA in comparison to wild-type E. coli WP2at concentrations of 10^30 /^g/ml in agar diffusion assays. Both compounds were inducers of cell filamentation and prophage X (two E. coli SOS functions) at concentrations of 0.1~l //g/ml. In addition, the ability of PD 114,759 and PD 115,028 to retain their filamentation-inducing effects under both aerobic conditions and anaerobic conditions suggests that a bioreductive, rather than an oxygen-requiring, mechanism is involved in the DNA-reactive effects of these agents.
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PD 114,759 (veractamycin A) and PD 115,028 (veractamycin B) are two major components of an antibiotic complex produced by Actinomadura verrucosospora subsp. veractimyces ATCC393631~3). These antibiotics have marked antimicrobial activity, with minimal inhibitory concentrations of <6 pg/ml against several bacteria^. More importantly, they have marked antitumor effects in vitro against a variety of murine and humantumor cell lines, and in vivo against murine LI210 leukemia, B16 melanoma, M5076 sarcoma, Ridgway osteosarcoma, and the MX-1human mammary xenograft1'^. With respect to the mechanism of action of these antibiotics, Fry et al. have Escherichia coli WP2/WP100 uvrA recA DNARepair Assay E. coli DNArepair (differential toxicity) assays were performed as well-agar diffusion assays based on methods described by Mamberet al.5\ Either 12 or 7 mmdiameter wells were cut in minimal glucose agar plates supplemented with casein hydrolysate (500 mg/liter) and L-tryptophan (20 mg/liter) seeded with either E. coli WP2or E. coli WP100in a soft (1 %) agar overlay. Samples (80^1/12 mm well or 50^1/7 mmwell) of a given test agent at varying concentrations were dispensed in triplicate vs. each strain. After incubating plates at 37°C for 24 hours, the diameters of the zones of growth inhibition were measured. Differential inhibition values (mean zone size difference) at each concentration were calculated as the mean inhibition zone vs. strain WP100minus the mean inhibition zone vs. strain WP2. A mean zone size difference exceeding 3 mmfor at least one test concentration was considered to be positive for repairable DNAeffects. E. coli K-12 SOS Chromotest E. coli K-12 SOSchromotest agar spot tests were performed using methods described by Mamber et alP. Briefly, 20 iA aliquots of samples of varying concentrations were spotted directly onto the surface of LBagar trays or plates seeded with E. coli PQ37. After incubation at 37°C for 18~24 hours, a colorimetric indicator overlay containing 6-bromo-2-naphthol-i8-D-galactopyranoside (Sigma Chemicals, St. Louis, MO, U.S.A.) and fast blue RR salt (Sigma) was prepared and poured onto the agar surface. Positive results were manifested by the presence of a red color (indicative of /3-galactosidase activity) at the site of sample application. The size of the colored zone and the color intensity were used to obtain a semiquantitative measure of DNAeffects.
To investigate the effects of aerobic vs. anaerobic incubation of chromotest plates on the DNA reactivity of PD 114,759 and PD115,028, a comparative chromotest was performed using plates incubated under normal (aerobic) conditions and plates spotted with identical samples but incubated in Gaspak anaerobic jars (BBL, Cockeysville, MD). After incubation at 37°C for 18~24 hours, colorimetric overlays were prepared and poured onto all plates.
E. coli K-12 Bacteriophage Induction Assay (BIA) Assays for prophage induction in E. coli K-12 strains BR513 and BR339 were performed using agar spot test methods6>7). Briefly, 20 [A aliquots of samples of varying concentrations were spotted in duplicate onto LBE+ ampicillin (10^g/ml) agar trays seeded with a given tester strain. The cell wall of strain BR339was made more permeable to test agents by treating the cells with Trizma-HCl (Sigma) prior to seeding the agar6'8). After incubation at 37°C for 4 hours, a colorimetric indicator overlay (same as that for the chromotest) was prepared and poured onto the surface of the agar. The size of the colored zone (/3-galactosidase activity) and intensity of the red color surrounding the site of application of a given sample were used to evaluate DNAeffects.
Results
Both PD 114,759 and PD 115,028 showed DNAreactivity in all microbial tests. In the differential Fig. 1 . Differential toxicity of PD 114,759 (O), PD 115,028 (à"), bleomycm (a), daunomycin (a), mitomycin C (å¡) and streptonigrin (H) in the Escherichia coli WP2/WP100 uvrA recA DNArepair assay.
Inhibition zone size difference=(inhibition zone for strain WP100)-(inhibition zone for strain WP2).Each point represents the meanof 3 replicate samples spotted against each tester strain.
In the E. coli assay for repairable DNAdamage, PD 114,759 and PD 1 15,028 showed preferential toxicity toward DNArepair mutant WP100(mean zone size differences between strains WP100and WP2 exceeded 3 mm) at concentrations higher than that for mitomycin C and streptonigrin, and lower than that for daunomycin (Fig. 1) . However, PD 114,759 and PD 115,028 appeared to show less repairable DNA-damaging effects than the latter 3 compoundswhenone takes into account the magnitude of the dose-response relationship, i.e., the differential toxicity of the veractamycins varied from 3^4 mmover the range of concentrations tested, whereas the differential toxicity of daunomycin, mitomycin C and streptonigrin varied from 3~15 mmover a similar concentration range. It should be cautioned that the variability in agar diffusion rates of the compoundsmayplay a role in the validity of these potency comparisons, and that liquid suspension (treat-and-plate) assays may be more appropriate for comparing the DNA-reactive potencies of these agents. Still, the results indicate that PD 114,759 and PD 1 15,028 are only weakly/moderately effective in causing DNAlesions in E. coli WP100 uvrA recA in comparison to wild-type strain WP2. Similarly, E. coli WP100showed no increased sensitivity to bleomycin relative to strain WP2; the inability of bleomycin to preferentially kill E. coli DNArepair mutants relative to repair-proficient strains has been observed by other investigators9"1^. It has been hypothesized that bleomycin may be producing concentrated DNAdamage in a confined, specific region of the E. coli genome, and that such DNAdamage is essentially non-repairable even in the DNArepair-proficient strainsll"150. Because PD 114,759 and PD115,028 show relatively weak preferential killing of the DNArepair mutant in this study, it may be hypothesized that the veractamycins produce DNAlesions in E. coli that are only partially repairable by excision repair and postreplication repair mechanisms.
The results of the tests for induction of prophage and of cell filamentation, two SOS functions of E. coliu>15:>, provided further insight into the mechanism of DNAreactivity of the veractamycins. PD 114,759 and PD 115,028 were potent inducers of prophage 1 (BIA) and cell filamentation (chromotest), as were the four above-named antitumor antibiotics. These findings indicate that the veractamycins are capable of interfering with bacterial DNAreplication. In the BIA, PD 114,759 and PD 115,028 were capable of inducing prophage both in E. coli strains BR513 and BR339, whereas bleomycin was active only against strain BR513.This provides evidence that the specific mechanism of DNAreactivity of the veractamycins markedly differs from that of bleomycin, despite similar bleomycin and veractamycin effects in the E. coli WP2/WP100 DNArepair assay. Fry et al.4 ) also found significant differences in the DNA-reactive effects of bleomycin as compared to PD 1 14,759 in alkaline elution and other biochemical assays.
The most important insight into the mechanism of DNAreactivity, however, comes from the comparison of the E. coli chromotest results for the plates incubated aerobically and anaerobically. In these tests, PD 114,759 and PD 115,028 most resembled mitomycin C, in that all 3 compounds showed equivalent activity for anaerobic vs. aerobic incubation. In contrast, bleomycin and streptonigrin were 30~100-fold less active when plates were incubated anaerobically as compared to the aerobicallyincubated plates. Both bleomycin and streptonigrin require oxygen to exert their DNA-reactive effects, whereas mitomycin C acts as a bioreductive alkylating agent13>16~22). This suggests that the specific mechanism of DNAreactivity by PD 114,759 and PD 115,028 is a reductive, process that does not require the presence of oxygen. It can further be hypothesized that, like mitomycin C, PD 114,759 and PD 115,028 may be active against hypoxic tumor cells. In vitro cytotoxicity tests on oxic vs. hypoxic cells are necessary to confirm this hypothesis.
In summary, PD 114,759 and PD 115,028 are capable of causing repairable DNAdamage and the induction of SOSfunctions in E. coli. The veractamycins appear to have their own unique DNAmodifying properties, although they share properties common to other important DNA-reactive antitumor antibiotics. The results suggest that PD 114,759 and PD 1 15,028 cause fairly concentrated DNAdamage in the microbial genome, and that the mechanism by which the DNAis damaged appears to involve bioreduction rather than oxidation. It is hoped that the observations made using the microbial systems are applicable to the interactions of the veractamycins with mammaliantumor cell DNA.
